



# TRUST THE EVIDENCE

## SENVELGO® ASSESSED IN MORE THAN 300 CATS

*Proven efficacy and quality of life with  
the only once-daily oral solution for feline diabetes*



# Efficacy and safety of once-daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice-daily insulin injection in diabetic cats



Niessen SJM et al. *J Vet Intern Med.* 2024;38:2099-2119.<sup>1</sup>

## SEVELGO<sup>®</sup> is at least as effective as insulin in treating feline diabetes, and achieves faster glycaemic control

Mean blood glucose in SEVELGO<sup>®</sup>-treated and insulin-treated cats.



Blood glucose target range: 3.5 to 14 mmol/L

- Glycaemic control achieved in most SEVELGO<sup>®</sup>-treated cats by day 7
- Clinical improvements were comparable between SEVELGO<sup>®</sup>-treated and insulin-treated cats

— Once-daily oral SEVELGO<sup>®</sup>  
— Twice-daily injectable insulin

**81% of owners said that SEVELGO<sup>®</sup> improved their cat's quality of life.**

## No clinical hypoglycaemia in SEVELGO<sup>®</sup>-treated cats

Main adverse events in SEVELGO<sup>®</sup>-treated and insulin-treated cats.


ADVERSE EVENTS	SEVELGO <sup>®</sup> (%)	INSULIN (%)
Non-clinical hypoglycaemia	13	53
Clinical hypoglycaemia	0	8
Soft stool/diarrhoea	38	15
Positive urine culture	31	27
Diabetic ketoacidosis (DKA)	7	0

The most common side-effect:

- In SEVELGO<sup>®</sup>-treated cats was mild, self-limiting soft stool/diarrhoea, likely due to SGLT inhibition in the intestine
- In insulin-treated cats was hypoglycaemia

## Study design

Results of the inclusion/exclusion process of the study.



- Prospective, randomised, positive-controlled, open-label, non-inferiority clinical field trial
- Initial 45-day treatment success analysis, with efficacy and safety of long-term use evaluated until day 91

## Primary endpoint

The primary efficacy assessment was to assess for non-inferiority of the SENVELGO<sup>®</sup>-treated group compared with the insulin-treated group. Treatment success was defined as improvement in at least one glycaemic variable and one clinical sign on day 45.

## STUDY CONCLUSION

Once-daily oral SENVELGO<sup>®</sup> is a treatment option for feline diabetes that is as effective as insulin, improves feline quality of life, does not result in episodes of clinical hypoglycaemia, and simplifies current management strategies.




# Velagliflozin, a once-daily, liquid, oral SGLT2 inhibitor, is effective as a stand-alone therapy for feline diabetes mellitus: the SENSATION study.



Behrend EN et al. *J Am Vet Med Assoc.* 2024;262:1343-1353.<sup>2</sup>

## SEVELGO® delivers rapid and sustained clinical improvement and glycaemic control

*Improvement rates in clinical signs compared with screening.*



- **Over 54%** of owners reported improvement in polyuria and polydipsia by **day 7** of treatment with over 88% of cats showing improvement at 6 months
- Glycaemic control\* was achieved **by day 7 and sustained** throughout the 6-month study, with **over 80%** of cats demonstrating glycaemic control at 6 months

***SEVELGO® was well accepted by cats, with over 98% of doses administered successfully.***



## No clinical hypoglycaemia in SEVELGO®-treated cats

The adverse event profile was similar to the Niessen et al. study.<sup>1</sup>

Test for ketones (e.g. in the urine) every 1-3 days and immediately if the cat becomes unwell during the first 2 weeks of treatment.

\*Glycaemic control was defined as glucose and/or fructosamine within their reference ranges.

## Study design

Results of the inclusion/exclusion process of the study.




- Prospective, baseline-controlled, open-label, clinical field trial. All cats received 1 mg/kg SENVELGO® orally once daily
- Study evaluated safety and efficacy over a 30-day period, with the option for continued use until 6 months

## Primary endpoint

The study authors hypothesised that more than 70% of cats would have improvement in at least one glycaemic parameter on day 60 and in at least one clinical sign on day 180.

## STUDY CONCLUSION

The initial hypothesis was validated: SENVELGO® improved glycaemic parameters and clinical signs in diabetic cats. SENVELGO® provides a convenient alternative to insulin as a stand-alone treatment of diabetic cats.



# TWO RIGOROUS APPROACHES

## LEND SUPPORT TO SENVELGO®

FEATURE	NIESSEN ET AL. STUDY <sup>1</sup>	BEHREND ET AL. STUDY <sup>2</sup>
Field trial type	 Prospective, open-label	 Prospective, open-label
Control	 Insulin	 Baseline
Number of cats	 127	 252
Proportion of insulin-pretreated cats	 31%	 15%
Length of initial efficacy and safety phase in days	 45	 30
Length of extended use phase in days	 91	 180
Treatment success defined as improvement in at least...	 One glycaemic variable (median BG $\leq$ 14 mmol/L) and one clinical sign 	 One glycaemic variable (median BG $\leq$ 16 mmol/L) and one clinical sign 
Clinical signs started to improve by day*	 3	 3
Blood glucose started to improve by day*	 7	 7
Most common side effect	 Mild, transient loose stools/diarrhoea	 Mild, transient loose stools/diarrhoea

\* Day 3 and day 7 were the first timepoints after treatment initiation at which data was collected for clinical signs and glycaemic parameters respectively

# SEE THE LIFE-CHANGING EFFECTS OF SENVELGO®



Proven efficacy in naïve and insulin-pretreated diabetic cats in two large-scale clinical studies lasting up to 6 months



Once-daily oral solution that can be administered directly into the cat's mouth or applied onto a small amount of food



Reduces hyperglycaemia, leading to sustained glycaemic control within 1 week



Improvement in clinical signs leading to a better quality of life



No episodes of clinical hypoglycaemia



No glucose curves required



Formulation well accepted by cats



Created through collaboration between human and animal diabetes research



*GB packaging shown for illustrative purposes*

# TRUST THE EVIDENCE

## RELY ON SENVELGO®

The only once-daily oral solution for feline diabetes, easy-to-use and well accepted by cats

Delivers fast, reliable and sustained glucose control, while eliminating the risk of clinical hypoglycaemic events and improving quality of life<sup>1,2</sup>

---

*Make SENVELGO® your simple solution for diabetic cats and their owners.*

---



#### References:

1. Niessen, S. J. M. et al. (2024) Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats. ] Vet Intern Med 38, 2099–2119
2. Behrend, E. N. et al. (2024) Velagliflozin, a once-daily, liquid, oral SGLT2 inhibitor, is effective as a stand-alone therapy for feline diabetes mellitus: the SENSATION study. JAVMA 262, 1343-1353

Senvelgo® contains velagliflozin (sodium-glucose co-transporter 2 [SGLT-2] inhibitor). UK: POM-V IE: POM. Prescription decisions are for the person issuing the prescription alone. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: 01344 746959 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries). Email: [vetenquiries@boehringer-ingelheim.com](mailto:vetenquiries@boehringer-ingelheim.com). Senvelgo® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence. ©2025 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: Aug 2025. UI-PET-0233-2025. Use Medicines Responsibly.